Opacity (optics)

Pantheon Vision Announces Two Successful Pre-Submission Meetings With the FDA

Retrieved on:

Wednesday, April 17, 2024

FDA, Optical, Health, Medical Devices, Opacity (optics), Vision, Surgeon, PMA, Corneal opacity, Paratriathlon, Food, Pharmaceutical industry

Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants to eliminate corneal blindness, announced today the completion of two successful and productive Pre-Submission meetings with the U.S. Food and Drug Administration (FDA).

Key Points:

Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants to eliminate corneal blindness, announced today the completion of two successful and productive Pre-Submission meetings with the U.S. Food and Drug Administration (FDA).
Pantheon Vision requested these early interactions with the FDA review team to obtain agency guidance on preclinical and clinical work supporting a Premarket Approval (PMA) submission.
“We are thrilled with the results of the Pre-Submission meetings with the FDA as this is a pivotal step towards a PMA acceptance.
This interactive meeting was an opportunity for us to gather feedback before our planned premarket submission,” said John Sheets, President and CEO, Pantheon Vision.

Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium

Retrieved on:

Wednesday, March 27, 2024

Opacity (optics), Risk, Patient, RBS, University, PDAT, Bascom Palmer Eye Institute, Rose bengal, Eye, Infection, Keratitis, Safety, Paratriathlon, Ophthalmology, OBC, Pharmaceutical industry

Provectus would contribute the license to the new entity and have an exclusive RBS supply arrangement with it.

Key Points:

Provectus would contribute the license to the new entity and have an exclusive RBS supply arrangement with it.
Rose bengal PDAT emerged under the leadership of Jean-Marie Parel, IngETS-G, Ph.D., FARVO, Director of the Ophthalmic Biophysics Center (“OBC”) at Bascom Palmer Eye Institute (“BPEI”) at the University of Miami Miller School of Medicine.
The OBC team and Dr. Parel have spent many years advancing their PDAT technology using rose bengal against different types of treatment-naïve and -resistant keratitis.
Dr. Parel said, “Rose bengal PDAT is the result of a lot of hard work by cross-disciplinary contributors at the University of Miami.

Pantheon Vision Secures a Second Tranche of $1.8 Million to Advance Bioengineered Corneal Implants

Retrieved on:

Tuesday, April 2, 2024

Biotechnology, Optical, Health, Medical Devices, KLI, Opacity (optics), Vision, Paratriathlon, FDA, Developing country, Food

Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants to eliminate corneal blindness, announced the closing of $1.8 million in a second tranche from KeraLink International (KLI).

Key Points:

Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants to eliminate corneal blindness, announced the closing of $1.8 million in a second tranche from KeraLink International (KLI).
This comes on the heels of a previous $2.5 million investment from last year, also from KLI, bringing the total funding to $4.3 million.
The funds will be used to advance Pantheon Vision’s development of bioengineered corneal implants to reduce reliance on donated corneal tissue.
“The additional funding from KLI positions Pantheon Vision to advance our bioengineered corneal implants to treat corneal blindness,” said John Sheets, President and CEO, Pantheon Vision.

ERS Genomics and StemSight Sign CRISPR/Cas9 License Agreement

Retrieved on:

Wednesday, January 17, 2024

ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and StemSight Oy (‘StemSight’), a biotechnology company developing stem cell based therapies for corneal blindness, today announced a non-exclusive CRISPR/Cas9 license agreement.

Key Points:

ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and StemSight Oy (‘StemSight’), a biotechnology company developing stem cell based therapies for corneal blindness, today announced a non-exclusive CRISPR/Cas9 license agreement.
The agreement grants StemSight access to ERS’ CRISPR/Cas9 patent portfolio.
Dr Laura Koivusalo, CEO and Co-founder of StemSight, said: “This partnership with ERS Genomics is a significant leap forward for StemSight.
With 89 patents held in over 90 countries, ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.

KeraLink International Launches the Great Cornea Challenge and a Cornea Technology Accelerator

Retrieved on:

Monday, December 11, 2023

Biotechnology, Medical Devices, Other Health, Health, Optical, Eye, Challenge, Accelerator, Infection, Ultralight aviation, Opacity (optics), Documentation, PEN, Poverty, Green, KLI, Cryptocurrency, Developing country

KeraLink International (KLI) today announced the launch of the Great Cornea Challenge and the Cornea Technology Accelerator.

Key Points:

KeraLink International (KLI) today announced the launch of the Great Cornea Challenge and the Cornea Technology Accelerator.
The Great Cornea Challenge invites entrepreneurs and innovators to propose new products, services, or technologies for preventing, detecting, and treating corneal blindness in LMICs.
Ultralight founder and CEO Monik Sheth stands behind the work of KeraLink International and its mission to eradicate corneal blindness.
We love supporting the types of founders and innovations that the Great Cornea Challenge is attracting," Sheth said.

KeraLink International Provides $2.5 Million in Seed Funding to Enable Development of Bioengineered Corneal Implants

Retrieved on:

Monday, November 13, 2023

Biotechnology, Optical, Health, Medical Devices, Eye, Vision, Johnson & Johnson, Organization, Food, Alcon, Infection, Opacity (optics), PEN, Bausch & Lomb, KLI, PV, Cryptocurrency, Developing country

Pantheon Vision, an early-stage ophthalmic medical device company KLI established, will use the funding to develop bioengineered corneal implants to reduce reliance on donated corneal tissue – often unavailable in LMICs.

Key Points:

Pantheon Vision, an early-stage ophthalmic medical device company KLI established, will use the funding to develop bioengineered corneal implants to reduce reliance on donated corneal tissue – often unavailable in LMICs.
“Development of novel therapeutic solutions is costly but critical to fulfilling our mission of eradicating corneal blindness,” said Douglas J. Furlong, KLI Board Chairman.
More than 12.7 million children and adults are blind because of corneal injuries or infections, and millions more are blind in one eye or live with seriously impaired vision.
KLI is rewriting the narrative of corneal health by advancing ground-breaking products, technologies, and services to eradicate corneal blindness with specific emphasis on low- and middle-income countries.

Pantheon Vision Raises $2.5 Million in Seed Funding to Launch Development of Bioengineered Corneal Implant

Retrieved on:

Thursday, November 2, 2023

Bausch & Lomb, FDA, Food, KLI, Organization, Hoya, Developing country, Alcon, Johnson & Johnson, Patient, Opacity (optics), Management, Pharmaceutical industry

BALTIMORE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pantheon Vision, an early-stage ophthalmic medical device company, has announced $2.5 million in seed financing from Baltimore-based KeraLink International (KLI).

Key Points:

BALTIMORE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pantheon Vision, an early-stage ophthalmic medical device company, has announced $2.5 million in seed financing from Baltimore-based KeraLink International (KLI).
"We are thrilled to have KeraLink provide our initial funding to establish Pantheon Vision as a company dedicated to bringing groundbreaking ophthalmic innovations to patients worldwide,” expressed John Sheets, Ph.D., Chief Executive Officer of Pantheon Vision.
“This funding enables us to advance our program to eradicate corneal blindness and restore vision.”
Pantheon Vision is creating bioengineered implants to raise the standard of eye care globally and reduce reliance on donated corneal tissue, which is often unavailable in low- and middle-income countries (LMICs).
The company will engage the U.S. Food and Drug Administration (FDA) in the coming months to guide plans for global product development.

World Sight Day is October 12, 2023 - HCP Cureblindness Shines Light on Avoidable Blindness and Its Mission to Help Individuals in Underserved Countries Retain and Regain Their Sight

Retrieved on:

Thursday, October 5, 2023

Held the second Thursday each October, World Sight Day is an annual day of awareness to focus global attention on blindness and vision impairment.

Key Points:

Held the second Thursday each October, World Sight Day is an annual day of awareness to focus global attention on blindness and vision impairment.
90% of these individuals live in low-to-middle income countries, where poor nutrition and limited access to eye care can mean a life limited by needless blindness.
"This World Sight Day, HCP is shining a light on why avoidable blindness can – and must – be overcome," said K-T Overbey, HCP's Chief Executive Officer.
"This World Sight Day, everyone should learn the easy steps to help the millions who are blind or who have moderate-to-severe vision impairment."

KeraLink International Unveils Groundbreaking Strategy to Eradicate Corneal Blindness

Retrieved on:

Monday, August 28, 2023

KeraLink International (KLI), a globally renowned charitable organization and leader in corneal health innovation, today unveiled three major initiatives to eradicate corneal blindness in low- and middle-income countries (LMICs): supporting the development of a groundbreaking approach to corneal regeneration; advancing a wholistic global strategy for preventing and treating corneal conditions that may lead to blindness; and spearheading a collaborative international effort to combat infectious keratitis, the leading cause of corneal blindness globally.

Key Points:

KeraLink International (KLI), a globally renowned charitable organization and leader in corneal health innovation, today unveiled three major initiatives to eradicate corneal blindness in low- and middle-income countries (LMICs): supporting the development of a groundbreaking approach to corneal regeneration; advancing a wholistic global strategy for preventing and treating corneal conditions that may lead to blindness; and spearheading a collaborative international effort to combat infectious keratitis, the leading cause of corneal blindness globally.
“KeraLink International is unique in our singular focus on bringing health care providers, technology innovators, philanthropists, and investors into a coordinated, collaborative effort to eliminate corneal blindness in LMICs,” said Douglas J. Furlong, Board Chairman, KLI.
In the U.S., untreated corneal blindness is essentially a condition of the past.
Corneal blindness affects 12.7 million children and adults and threatens tens of millions more, even though it is preventable, treatable, and reversible.

Eluminex Biosciences Receives Scientific Recognition for its Recombinant Human Collagen (rhCIII) Biosynthetic Cornea (EB-301) Program to Treat Corneal Blindness

Retrieved on:

Tuesday, May 16, 2023

SUZHOU, China and SAN FRANCISCO, May 16, 2023 /PRNewswire/ -- Eluminex Biosciences (Eluminex) announced that its clinical pivotal study (CLARITY) evaluating a novel biosynthetic corneal implant (EB-301) currently being conducted in China was recognized for its groundbreaking work at two recent international ophthalmology meetings held in the United States.

Key Points:

Eluminex's poster presentation entitled "A novel recombinant human collagen III (rhCIII) biosynthetic cornea (EB-301) to treat corneal blindness: initial results of the CLARITY Study" (poster 88312) presented on May 7, 2023, received honorable mention recognition in the category of Cornea.
The ASCRS annual meeting is an internationally recognized scientific symposium for clinicians and researchers in the field of cataract, refractive, cornea and glaucoma surgery.
The EB-301 investigational corneal implant is manufactured from recombinant human Type III collagen (rhCIII) and is intended to treat corneal blindness secondary to stromal lesions amenable to anterior lamellar keratoplasty (ALK) surgery as an alternative to human cadaveric corneal transplants.
Corneal blindness is a leading cause of vision loss globally; however, it is estimated that over half the world's population has no access to a corneal transplant.